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Summary
 
Mycobacterium tuberculosis
 
 and other pathogenic mycobacteria export abundant quantities of pro-
teins into their extracellular milieu when growing either axenically or within phagosomes of
host cells. One major extracellular protein, the enzyme glutamine synthetase, is of particular in-
terest because of its link to pathogenicity. Pathogenic mycobacteria, but not nonpathogenic my-
cobacteria, export large amounts of this protein. Interestingly, export of the enzyme is associated
 
with the presence of a poly-
 
l
 
-glutamate/glutamine structure in the mycobacterial cell wall. In this
study, we investigated the influence of glutamine synthetase inhibitors on the growth of patho-
genic and nonpathogenic mycobacteria and on the poly-
 
l
 
-glutamate/glutamine cell wall structure.
The inhibitor 
 
l
 
-methionine-
 
S
 
-sulfoximine rapidly inactivated purified 
 
M
 
.
 
 tuberculosis
 
 gluta-
mine synthetase, which was 100-fold more sensitive to this inhibitor than a representative
 
mammalian glutamine synthetase. Added to cultures of pathogenic mycobacteria, 
 
l
 
-methionine-
 
S
 
-sulfoximine rapidly inhibited extracellular glutamine synthetase in a concentration-dependent
manner but had only a minimal effect on cellular glutamine synthetase, a finding consistent
with failure of the drug to cross the mycobacterial cell wall. Remarkably, the inhibitor selec-
tively blocked the growth of pathogenic mycobacteria, all of which release glutamine synthe-
tase extracellularly, but had no effect on nonpathogenic mycobacteria or nonmycobacterial micro-
organisms, none of which release glutamine synthetase extracellularly. The inhibitor was also
bacteriostatic for 
 
M
 
.
 
 tuberculosis
 
 in human mononuclear phagocytes (THP-1 cells), the pathogen’s
primary host cells. Paralleling and perhaps underlying its bacteriostatic effect, the inhibitor mark-
edly reduced the amount of poly-
 
l
 
-glutamate/glutamine cell wall structure in 
 
M
 
.
 
 tuberculosis
 
.
Although it is possible that glutamine synthetase inhibitors interact with additional extracellular
proteins or structures, our findings support the concept that extracellular proteins of 
 
M
 
.
 
 tuberculosis
 
and other pathogenic mycobacteria are worthy targets for new antibiotics. Such proteins con-
stitute readily accessible targets of these relatively impermeable organisms, which are rapidly
developing resistance to conventional antibiotics.
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T
 
he seemingly inevitable emergence of strains of patho-
genic microorganisms resistant to current antibiotics
imposes a continuing need for novel strategies for antibiotic
development. This need is particularly urgent in the case of
tuberculosis, the world’s leading cause of death from a sin-
gle infectious agent. Strains of 
 
Mycobacterium tuberculosis
 
, the
primary causative agent of tuberculosis, have emerged world-
wide that are resistant to the major antibiotics used to treat
this disease (1).
Antibiotics typically target key cell wall or intracellular
molecules of microorganisms that are involved in cell wall,
protein, or DNA synthesis, or in an essential metabolic path-
way. On the basis of studies in this report, we shall propose
an additional site for antibiotic targeting: extracellular en-
zymes released by a bacterium.
 
M
 
.
 
 tuberculosis
 
, along with other pathogenic mycobacteria,
is unusual among bacterial species in that it secretes or oth-
erwise releases a large number of proteins in considerable
quantities into its extracellular milieu. Such extracellular
proteins are released by 
 
M
 
.
 
 tuberculosis
 
 organisms when
growing either in broth medium or intraphagosomally in
human mononuclear phagocytes, the bacterium’s primary
host cells (2, 3). Approximately 100 proteins are released
into broth medium by 
 
M
 
.
 
 tuberculosis
 
, 11 of which are re- 
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leased in great abundance (4). One of the abundantly
released proteins is the enzyme glutamine synthetase (EC
6.3.1.2), which is surprising because this enzyme is typically
located in the bacterial cytoplasm (5). Even more surpris-
ing, only pathogenic mycobacteria such as 
 
M
 
.
 
 tuberculosis
 
and 
 
Mycobacterium bovis
 
 release large amounts of glutamine
synthetase extracellularly, whereas nonpathogenic mycobac-
teria, such as 
 
Mycobacterium smegmatis
 
 and 
 
Mycobacterium phlei
 
,
and nonmycobacterial microorganisms, such as 
 
Legionella
pneumophila
 
 and 
 
Escherichia coli
 
, do not (5).
Interestingly, the release of glutamine synthetase by patho-
genic mycobacteria is correlated with the presence of a
poly-
 
l
 
-glutamate/glutamine component in the cell walls
of these organisms; nonpathogenic mycobacteria lack this
component (6, 7). This suggests the possibility that extra-
cellular glutamine synthetase is involved in the synthesis of
poly-
 
l
 
-glutamate/glutamine and that the enzyme’s extra-
cellular presence is significant to virulence.
In this report, we shall demonstrate that an irreversible
inhibitor of 
 
M
 
.
 
 tuberculosis
 
 extracellular glutamine synthe-
tase blocks bacterial multiplication both in broth medium
and in human mononuclear phagocytes and that growth
inhibition is correlated with a marked reduction in the
amount of the virulence-associated cell wall component
poly-
 
l
 
-glutamate/glutamine. Remarkably, the enzyme in-
hibitor has no effect against nonpathogenic mycobacteria,
which do not export glutamine synthetase. Although the
inhibitor of glutamine synthetase may target additional ex-
tracellular proteins, our report provides strong evidence for
the concept that targeting extracellular proteins of patho-
genic mycobacteria and perhaps other pathogens is a feasi-
ble strategy for developing new antibiotics.
 
Materials and Methods
 
Bacterial Cultures. E. coli 
 
DH5
 
a
 
, 
 
L. pneumophila 
 
Philadelphia 1,
the 
 
M. tuberculosis
 
 strains Erdman (35801; American Type Culture
Collection [ATCC]), H37Rv (25618; ATCC), and H37Ra
(25177; ATCC), 
 
M. bovis
 
 (19210; ATCC), 
 
M
 
.
 
 bovis
 
 BCG (bacille
Calmette-Guérin [19274; ATCC]), 
 
M. phlei 
 
(11758; ATCC), 
 
M.
smegmatis
 
 (14468; ATCC), and 
 
Mycobacterium avium
 
 (25291; ATCC)
were cultured as described (5).
 
Assays of Glutamine Synthetase Activity In Vitro. M
 
.
 
 tuberculosis
 
Erdman extracellular and intracellular glutamine synthetase was
purified as described (5) or by chromatography on Affi-Gel Blue
100–200 mesh (Bio-Rad Labs.) and size fractionation on Super-
dex 75 (Pharmacia Biotech, Inc.). Active fractions were dialyzed
against 15 mM imidazole, 2.2 mM MnCl
 
2
 
, pH 7, stored at 4
 
8
 
C,
and assessed for enzyme activity
 
 
 
by biosynthetic and transfer assay
as described (8). Proteins in the active fractions were analyzed by
denaturing PAGE and stained with Coomassie brilliant blue R or
silver nitrate. The NH
 
2
 
-terminal sequence of the extra- and in-
tracellular 
 
M
 
.
 
 tuberculosis
 
 glutamine synthetase (TEKTPDD) was
presented in our earlier report (5). In that report, we showed that
this NH
 
2
 
 terminus of active glutamine synthetase corresponds ex-
clusively to the DNA sequence of the 
 
gln
 
A1 gene. Although the
 
M
 
.
 
 tuberculosis
 
 genome contains four genes with domains homol-
ogous with other bacterial glutamine synthetases, the 
 
gln
 
A1 gene
has the highest overall homology, and it is not known whether
the other genes are transcribed or expressed (9). Protein concen-
 
trations were determined by incubation with bicinchoninic acid
reagent (Pierce Chemical Co.).
The amount and activity of extracellular glutamine synthetase
released by 
 
M
 
.
 
 tuberculosis
 
 or other microorganisms over their en-
tire growth period (16 h–6 wk) was determined by assaying ali-
quots of cell-free culture supernates, taken at hourly, daily, or
weekly intervals, for enzyme activity by the 
 
g
 
-glutamyltransferase
assay (8). The theoretical possibility of leakage of cytoplasmic
glutamine synthetase from dead or dying 
 
M
 
.
 
 tuberculosis
 
 cells was
assessed by monitoring the activity of the cytoplasmic marker
protein lactate dehydrogenase during the 6-wk growth period,
both in the culture supernate and in the cell pellet, using a com-
mercially available diagnostic kit (Sigma Chemical Co.). Extra-
cellular lactate dehydrogenase activity never exceeded 0.5% of in-
tracellular activity.
Activity and inhibition profiles of 
 
M
 
.
 
 tuberculosis
 
 Erdman, 
 
E
 
.
 
 coli
 
W (Sigma Chemical Co.), and sheep brain glutamine synthetase
(Sigma Chemical Co.) in the presence and absence of 
 
l
 
-methio-
nine-
 
S
 
-sulfoximine and 
 
d
 
,
 
l
 
-phosphinothricin (a gift from David
Eisenberg, University of California at Los Angeles, Los Angeles,
CA) were determined for 1 U of each enzyme in 50 mM MgCl
 
2
 
 as
described, using the biologically relevant biosynthetic reaction for
all assays (8). 
 
K
 
m
 
 and 
 
K
 
i
 
 values for the three enzymes were calcu-
lated as described (10, 11). 
 
K
 
i
 
 values were determined by plotting
reciprocal values for the reaction velocity versus substrate con-
centration for concentrations of the 
 
l
 
-glutamate substrate ranging
from 2.5 to 100 mM and for concentrations of the inhibitor rang-
ing from 2 to 200 
 
m
 
M in the enzyme assays. 
 
K
 
i
 
 values, determined
in triplicate assays, were expressed as 
 
K
 
i
 
 
 
5 
 
K
 
m
 
 
 
3
 
 [I] / (
 
K
 
m
 
 
 
2
 
K
 
m(app)
 
). Direct analyses of cell pellets and culture supernates for
glutamine synthetase activity were performed using the transfer
reaction. The recombinant 
 
M
 
.
 
 tuberculosis
 
 glutamine synthetase,
which was cloned in the 
 
E
 
.
 
 coli
 
/mycobacterial shuttle vector
pNBV-1 as a genomic DNA fragment containing the structural
gene plus extensive flanking regions (12), was expressed in 
 
M
 
.
 
smegmatis
 
 and exported into the extracellular milieu (12). Re-
combinant glutamine synthetase was purified, and its enzymatic
activity and inhibition profile were determined as described
above for the endogenous enzymes.
 
Inhibition of Bacterial Cultures by 
 
l
 
-Methionine-S-Sulfoximine
and 
 
d,l
 
-Phosphinothricin.
 
Broth cultures of bacteria were inocu-
lated at a density of 1–5 
 
3
 
 10
 
5
 
 cells/ml and grown until station-
ary phase was reached (overnight–6 wk). Various amounts of
 
l
 
-methionine-
 
S
 
-sulfoximine; 
 
d
 
,
 
l
 
-phosphinothricin; the standard
antituberculous antibiotics amikacin, ethambutol, isoniazid, pyra-
zinamide, and rifampin (Sigma Chemical Co.); or 
 
l
 
-glutamate/
glutamine were added at time points specified in the figure legends.
Viable cells in each culture were determined by removing culture
aliquots, plating washed bacteria on appropriate growth media,
and enumerating colonies after standard incubation periods (over-
night–2 wk).
 
Inhibition of Mycobacterial Growth in Human Monocytes.
 
THP-1
cells, a human acute monocytic leukemia line (TIB 202; ATCC),
were seeded at 10
 
7
 
 cells/ml, differentiated with 100 nM PMA
(Sigma Chemical Co.), infected with freshly grown 
 
M
 
. tuberculosis
Erdman or M. avium bacteria at a multiplicity of 1 for 90 min
(thereby infecting 6–11% of the monocytes, based on a bacterial
count 3 h after infection), and cultured for up to 5 d in the pres-
ence of various concentrations of l-methionine-S-sulfoximine.
At various time points, THP-1 cell cultures were lysed by the ad-
dition of 0.1% SDS or by vortexing, and serial dilutions of the ly-
sates were plated on agar medium for the enumeration of viable
mycobacterial colonies (13).1427 Harth and Horwitz
Determination of Poly-l-Glutamate/Glutamine and d,l-Alanine in
the Cell Walls of l-Methionine-S-Sulfoximine–treated and –untreated M.
tuberculosis Bacteria. M. tuberculosis broth cultures in 7H9 or Sau-
ton’s medium (Difco Labs.) were inoculated at a density of 1–5 3
105 cells/ml and grown for 6 wk until stationary phase was
reached. l-methionine-S-sulfoximine was added, either at the
time of inoculation (0.2 and 2 mM final concentration) or after an
initial 2-wk growth period (20 and 200 mM final concentration),
to duplicate cultures. A second and third set of duplicate cultures
were inoculated in parallel and treated with amikacin (0.06–1 mg/
ml) or rifampin (0.0125–0.2 mg/ml) after 2 wk of cell growth.
The isolation of poly-l-glutamate/glutamine and the peptidogly-
can portion of the bacteria’s cell walls followed a procedure de-
scribed in an earlier report (6). In brief, the procedure involves (i)
treatment of disrupted cells with trypsin and chymotrypsin, (ii)
delipidation of cell walls by acetone and chloroform/methanol
extractions, (iii) acid hydrolysis of the cell walls, and (iv) precipi-
tation of the poly-l-glutamate/glutamine with hydrochloric acid
and redissolution in sodium hydroxide, a process that is repeated
several times before the final precipitate is washed with water and
lyophilized to obtain a pure white powder. The pellet after the
first redissolution in sodium hydroxide contains the peptidogly-
can chain. Both fractions, poly-l-glutamate/glutamine and pepti-
doglycan, were analyzed for their amino acid content after com-
plete acid hydrolysis.
Results
M. tuberculosis Glutamine Synthetase Is One to Two Orders
of Magnitude More Sensitive to the Inhibitors L-Methionine-
S-Sulfoximine and D,L-Phosphinothricin than a Representative
Mammalian Glutamine Synthetase. l-Methionine-S-sulfox-
imine and d,l-phosphinothricin are well characterized
inhibitors of prokaryotic and eukaryotic glutamine syn-
thetases (10, 11, 14). Preparatory to studying their effect on
growth of M. tuberculosis and other mycobacteria, we char-
acterized their effect on purified M. tuberculosis glutamine
synthetase. Additionally, we compared the sensitivity of M.
tuberculosis glutamine synthetase with a representative bacte-
rial glutamine synthetase, E. coli glutamine synthetase, and a
representative mammalian glutamine synthetase, sheep brain
glutamine synthetase.
We have previously reported the purification and char-
acterization of glutamine synthetase from the highly viru-
lent Erdman strain of M. tuberculosis (5). The homogeneous
enzyme is made up of 12 identical Mr z56–58,000 subunits
and active in the biosynthetic assay, with an apparent Km
value for l-glutamate of 2.7 6 0.2 mM, a specific activity
of 110 mmol Pi/min/mg enzyme, and a turnover number
of z70,000 (product/min/mol enzyme). Based on its mo-
lecular mass, structure, and biochemical features, the M. tuber-
culosis glutamine synthetase appears very similar to other
bacterial glutamine synthetases (15, 16).
To investigate the effect of glutamine synthetase inhibi-
tors on purified M. tuberculosis, E. coli, and sheep brain
glutamine synthetases, we first preincubated the enzymes in
l-glutamate–free reaction buffer for various times with
l-methionine-S-sulfoximine and d,l-phosphinothricin at fi-
nal concentrations of 2, 20, and 200 mM. We then assayed
the remaining biosynthetic activity of the enzyme over a
2-h period. The prokaryotic and eukaryotic glutamine syn-
thetases exhibited clear differences in sensitivity to the in-
hibitors (Fig. 1). In the presence of both inhibitors, the
prokaryotic glutamine synthetases rapidly lost their enzy-
matic activity; they retained ,10% of initial activity at 2 and
20 mM l-methionine-S-sulfoximine and at 2 mM d,l-phos-
phinothricin, and they were completely inactivated (#0.5%
initial activity) at higher concentrations of the inhibitors. In
contrast, sheep brain glutamine synthetase lost activity
much more slowly, retained a higher proportion of initial
activity throughout the incubation, and was not completely
inactivated at even the highest dose of each inhibitor. For
example, at inhibitor concentrations of 2 mM, the bacterial
enzymes retained only 3–10% of their initial activity,
whereas the sheep brain enzyme retained z40% of its ini-
tial activity in the presence of l-methionine-S-sulfoximine
and 60% in the presence of d,l-phosphinothricin. These
results thus confirm earlier reports that eukaryotic gluta-
mine synthetases are much more resistant to these two in-
hibitors than bacterial enzymes (10, 11).
Inactivation of all three glutamine synthetases was strictly
dependent on the presence of ATP and magnesium ions in
the incubation mix. The addition of l-glutamate to the incu-
bation mix at a final concentration of 100 mM substantially
protected the three enzymes, most likely by competing with
the inhibitors for the same binding site (10, 11, 14, 17). In
this regard, it is noteworthy that M. tuberculosis exports large
amounts of ATP into the extracellular milieu; the detectable
ATP concentration in a logarithmically growing culture is
z150–170  mM (5). However, even in the presence of
l-glutamate with very prolonged incubation (30, 60, and
120 min), the bacterial enzymes showed a significant de-
crease in activity: to z40–50% of the initial activity at 2 mM,
z20% at 20 mM, and z7.5% at 200 mM l-methionine-
S-sulfoximine and d,l-phosphinothricin. Under the same
conditions, the sheep brain enzyme retained z75% of its ini-
tial activity at 2 mM, z50% at 20 mM, and z25% at 200
mM l-methionine-S-sulfoximine and d,l-phosphinothricin.
To further compare the effect of the inhibitors on bacte-
rial and mammalian glutamine synthetase, we determined
the Km and Ki values for all three glutamine synthetases for
l-glutamate concentrations between 2.5 and 100 mM (Ta-
ble I). The Km results, ranging from 2.4 to 4.0 mM, con-
firmed our previous findings (5) and those described for the
E. coli and sheep brain enzymes (10, 11). The Ki values for
M. tuberculosis and E. coli glutamine synthetases in the pres-
ence of the irreversible inhibitor l-methionine-S-sulfox-
imine (1.1 and 1.3 mM, respectively) were two orders of
magnitude lower than the Ki value for sheep brain gluta-
mine synthetase (110.5 mM). The precision of the Ki values
per se was limited somewhat by the variation of z15%
around the calculated mean value for Vmax in the inhibition
curves. However, the data still allowed a valid comparison
between the bacterial and eukaryotic enzymes and con-
firmed that the eukaryotic enzyme is much more tolerant
to the two inhibitors than the bacterial enzymes.
Glutamine Synthetase Inhibitors Block the Growth of M. tuber-
culosis. Having determined that M. tuberculosis glutamine1428 Novel Drug Targets of M. tuberculosis
synthetase is sensitive to the inhibitors l-methionine-S-sul-
foximine and d,l-phosphinothricin, we examined the ef-
fect of the two inhibitors on the growth of M. tuberculosis.
We first added the inhibitors at final concentrations of 20,
200, and 2,000 mM to broth cultures of M. tuberculosis
Erdman strain (Fig. 2). The inhibitors had a profound effect
on the growth of the organism. l-methionine-S-sulfox-
imine at all three concentrations blocked cell growth al-
most immediately, whether added at the time the culture
was inoculated or 1–3 wk later. The effect of d,l-phosphi-
nothricin was less pronounced and not sustained; the cell
density of cultures treated with this inhibitor from the time
the culture was inoculated lagged the uninhibited cell cul-
tures by 0.5–1.5 log units. As l-methionine-S-sulfoximine
had such a sustained and apparently irreversible effect on
cell growth, we focused our subsequent investigations on
this inhibitor.
To determine the minimal inhibitory concentration of
l-methionine-S-sulfoximine on M. tuberculosis cultures,
we incubated the bacteria for 4 wk with 0, 0.2, 2, 20, and
200 mM of the inhibitor (Fig. 3 A). At the highest doses of
inhibitor, 20 and 200 mM, growth of M. tuberculosis was
Figure 1. Inactivation of vari-
ous glutamine synthetases by
l-methionine-S-sulfoximine and
d,l-phosphinothricin. The en-
zymes (1 U each) were preincu-
bated in the presence of ATP and
MgCl2 but in the absence of
l-glutamate, with each inhibitor
at the concentration indicated on
each panel. Aliquots in duplicate
were removed every minute,
diluted 100-fold in standard reac-
tion buffer, and assayed for re-
maining enzyme activity in the
biosynthetic reaction (8). Gluta-
mine synthetase activity, plotted vs.
time, is presented as a percentage
of the uninhibited control. In the
absence of inhibitors, the three
enzymes had similar levels of ac-
tivity (releasing z1.5 mmol inor-
ganic phosphate/120 min/10 mU
enzyme).1429 Harth and Horwitz
completely inhibited. At 2 mM of inhibitor, growth was
strongly inhibited, reaching its plateau at z2 log units be-
low that of the control cultures. At 0.2 mM of inhibitor,
growth was minimally inhibited, lagging the untreated
control cultures by z0.1–0.2 log units.
The results of the studies presented thus far suggested
that the inhibitory effect of l-methionine-S-sulfoximine
on M. tuberculosis growth may be due, at least in part, to the
inhibitor’s effect on the bacterial glutamine synthetase.
Studies in which the racemic inhibitors d,l-methionine-
S,R-sulfoximine or l-glutamine were added to M. tubercu-
losis broth cultures were consistent with this hypothesis. Of
the four racemic forms of the inhibitor, only l-methionine-
S-sulfoximine is active against glutamine synthetase (14). A
comparison of the inhibitory effect on M. tuberculosis growth
of l-methionine-S-sulfoximine and the racemate d,l-methi-
onine-S,R-sulfoximine showed that 4–5 times higher con-
centrations of the racemate were required to achieve the
same growth-inhibitory effect as l-methionine-S-sulfox-
imine at concentrations of 2, 20, and 200 mM. The addi-
tion of l-glutamine at concentrations 10–100-fold greater
than l-methionine-S-sulfoximine reversed the bacterio-
static effect of the inhibitor. At inhibitor concentrations of
0.2 and 2 mM, the reversal of growth inhibition was almost
complete, but at inhibitor concentrations of 20 and 200
mM, bacterial growth was only partially restored, lagging
uninhibited cultures by 0.4–1.3 log units.
The Glutamine Synthetase Inhibitor l-Methionine-S-Sulfoximine
Selectively Blocks the Growth of Bacteria that Export Glutamine
Synthetase. Our finding that the glutamine synthetase in-
hibitor l-methionine-S-sulfoximine strongly inhibits growth
of M. tuberculosis, a pathogenic mycobacterium that releases
large quantities of glutamine synthetase extracellularly, sug-
gested the possibility that bacterial sensitivity to the inhibi-
tor is correlated with enzyme release. We first tested this
hypothesis by studying the inhibitory effect of l-methio-
nine-S-sulfoximine on the growth of several other myco-
bacterial strains and subsequently extended the studies to
include nonmycobacterial strains as well (Fig. 3). Consis-
tent with this hypothesis, all pathogenic mycobacteria stud-
ied, including M. tuberculosis Erdman and H37Rv, M. bovis,
and M. bovis BCG, all of which release large amounts of
glutamine synthetase extracellularly, were highly sensitive
to l-methionine-S-sulfoximine, whereas all nonpathogenic
mycobacteria studied, including M. smegmatis and M. phlei,
and the nonmycobacterial species L. pneumophila Philadel-
phia 1 and E. coli DH5a, none of which release glutamine
synthetase extracellularly, were insensitive to the inhibitor
(Fig. 3). For the pathogenic mycobacteria, the patterns of
growth inhibition were very similar to those of M. tubercu-
losis. M. avium, an avian mycobacterium that is an opportu-
nistic pathogen for immunocompromised but not immu-
nocompetent humans, and that releases small quantities of
glutamine synthetase extracellularly, was intermediate be-
tween the highly pathogenic and nonpathogenic mycobacte-
ria in its sensitivity to l-methionine-S-sulfoximine (Fig. 3 F).
Extracellular Glutamine Synthetase Is a Prime Target of the
Inhibitor l-Methionine-S-Sulfoximine. The experiments de-
scribed above did not reveal whether the growth-inhibitory
effect of l-methionine-S-sulfoximine on M. tuberculosis was
correlated with inhibition of intracellular or extracellular
glutamine synthetase or both forms of the enzyme. To de-
termine the site of the inhibitor’s effect, we incubated M.
tuberculosis Erdman cultures with l-methionine-S-sulfox-
imine at 20 mM, a concentration that completely inhibits
M. tuberculosis growth over 4 wk, and assayed the levels of
intra- and extracellular glutamine synthetase activity by
transfer assay at weekly intervals (Fig. 4). In the absence of
inhibitor, the total detectable glutamine synthetase activity
was 58 mU of cell-associated vs. 23 mU of extracellular en-
zyme activity per 108 cells, a ratio of z2.5:1, nearly identi-
cal to our previously reported results (64 mU of cell-associ-
ated vs. 29 mU of extracellular enzyme activity per 108 cells,
a ratio of 2.2:1 [5]). In the presence of inhibitor, the level
of cell-associated glutamine synthetase activity was mini-
mally affected; activity plateaued at z50 mU, a 14% de-
crease from the uninhibited level (Fig. 4 A). In contrast, the
level of extracellular glutamine synthetase activity was re-
duced from the uninhibited level by 80%, from z23 mU to
z4.5 mU after 4 wk of growth (Fig. 4 B).
l-methionine-S-sulfoximine reduced the activity of ex-
tracellular glutamine synthetase but had no detectable effect
on the quantity of glutamine synthetase protein exported
by M. tuberculosis. Coomassie blue–stained polyacrylamide
gels showed no reduction in the amount of extracellular or
cell-associated glutamine synthetase in the presence of
inhibitor (data not shown). To confirm that l-methionine-
S-sulfoximine did not have a general effect on protein ex-
port, we analyzed its effect on the export and activity of
another large, multimeric, leaderless protein, M. tuberculosis
superoxide dismutase (18). Mycobacterial cultures treated
with 20 mM l-methionine-S-sulfoximine exhibited no re-
duction in activity or quantity of extracellular superoxide
dismutase compared with untreated cultures, as calculated
Table I. Biochemical Characteristics of M. tuberculosis, E. coli, and 
Sheep Brain Glutamine Synthetase
Species
Km
a
l-Glu
Ki
b
l-Ms
Ki
c
d,l-Ppt
mM mM mM
M. tuberculosis 2.4 1.1 0.6
E. coli 2.7 1.3 0.8
Sheep brain 4.0 110.5 16.4
aKm determined for l-glutamate (l-Glu) in the biosynthetic reaction.
bKi for l-methionine-S-sulfoximine (l-Ms) determined in the biosyn-
thetic reaction.
cKi for d,l-phosphinothricin (d,l-Ppt) determined in the biosynthetic
reaction and corrected for the active l-enantiomer.
Ki values were determined by plotting reciprocal values for the reaction
velocity versus l-glutamate concentration between 2.5 and 100 mM for
all three inhibitor concentrations assayed (2, 20, and 200 mM) and ex-
pressed as Ki 5 Km 3 [I]/Km 2 Km(app).
The SD for all presented values was #10%.1430 Novel Drug Targets of M. tuberculosis
on a per-cell basis. Moreover, on Coomassie blue–stained
polyacrylamide gels, none of the 12 major M. tuberculosis
extracellular proteins were reduced in the culture supernate
in the presence of inhibitor (data not shown).
l-methionine-S-sulfoximine also selectively inhibited ex-
tracellular glutamine synthetase activity of a recombinant
strain of M. smegmatis harboring a plasmid that allowed
the expression and export of recombinant M. tuberculosis
glutamine synthetase. In the absence of inhibitor, export of
endogenous glutamine synthetase by the parent and recom-
binant M. smegmatis strain was near the level of detection
(,1 mU), whereas export of M. tuberculosis glutamine syn-
thetase by the recombinant strain was 69 mU/108 cells; the
recombinant and endogenous glutamine synthetases were
readily differentiated by NH2-terminal amino acid analysis.
In the presence of 200 mM l-methionine-S-sulfoximine,
the level of extracellular glutamine synthetase activity of
the recombinant strain decreased 89%, whereas the level of
cell-associated glutamine synthetase activity (sum of endog-
enous and recombinant enzymes) decreased only 17%; the
growth rate of the parent and recombinant M. smegmatis
strain was unaffected by the inhibitor.
Inhibitory Effect of l-Methionine-S-Sulfoximine on Mycobac-
terial Growth in Human Monocytes. Before studying the ef-
Figure 2. Effect of l-methio-
nine-S-sulfoximine and d,l-phos-
phinothricin on the growth of
M. tuberculosis Erdman in broth
culture. Bacterial cultures in trip-
licate at an initial density of 105
bacteria/ml supplemented 7H9
medium were incubated for 6 wk
at 378C in a 5% CO2 atmo-
sphere. The glutamine synthetase
inhibitors  l-methionine-S-sul-
foximine and d,l-phosphinothri-
cin were added at the times and
concentrations indicated on each
panel. For the enumeration of
viable bacteria in each culture,
aliquots were removed weekly,
diluted, plated on solid medium,
and incubated for 2 wk at 378C
in a 5% CO2 atmosphere.1431 Harth and Horwitz
Figure 3. Effect  of  l-methionine-S-sulfoximine (MS) on the growth of various bacteria in broth
culture. The bacterial strains indicated were inoculated into an appropriate broth at an initial cell
density of 105 cells/ml, except M. avium (5 3 105 cells/ml) and L. pneumophila and E. coli (106 cells/
ml). Mycobacteria were cultured in supplemented 7H9 medium, L. pneumophila in yeast extract me-
dium, and E. coli in Luria-Bertani medium. All bacterial cultures were grown in the presence of var-
ious concentrations of l-methionine-S-sulfoximine, as indicated, at 378C and, except for E. coli, in a
5% CO2 atmosphere. M. tuberculosis, M. bovis, and M. avium were grown for 4 wk; M. smegmatis and
M. phlei for 3 d; L. pneumophila for 24 h; and E. coli for 6 h. For the enumeration of viable bacteria in
each culture, aliquots were removed weekly (M. tuberculosis, M. bovis, and M. avium), daily (M. smeg-
matis and M. phlei), every 4 h (L. pneumophila), or hourly (E. coli), plated on solid medium, and incu-
bated at 378C in a 5% CO2 atmosphere for 2 wk (M. tuberculosis, M. bovis, and M. avium), 3 d (M.
smegmatis and M. phlei), 24 h (L. pneumophila), or 12 h (E. coli). All cultures were in duplicate. For
each time point, the variation in the colony count averaged z5% and never exceeded 10%. (A) M.
tuberculosis Erdman; (B) M. tuberculosis H37Rv; (C) M. tuberculosis H37Ra; (D) M. bovis strain 19210;
(E) M. bovis strain BCG; (F) M. avium strain 25291; (G) M. smegmatis strain 1-2c; (H) M. phlei strain
11758; (I) L. pneumophila Philadelphia 1; (J) E. coli DH5a.1432 Novel Drug Targets of M. tuberculosis
fect of the glutamine synthetase inhibitor on M. tuberculosis
growing intracellularly in human monocytes, we first eval-
uated its effect on uninfected host cells. These studies showed
that l-methionine-S-sulfoximine at concentrations of 20 and
200 mM had no effect on the morphology, doubling time, or
viability of differentiated THP-1 human monocytes. This re-
sult was consistent with the relative insensitivity of eukaryotic
glutamine synthetases to inhibitors, as demonstrated for sheep
brain glutamine synthetase (Table I).
We next analyzed the effect of l-methionine-S-sulfoximine
on two different mycobacterial species, M. tuberculosis Erdman
and  M. avium (25291; ATCC), growing intracellularly in
THP-1 cells (Fig. 5, A and B). The enumeration of viable in-
tracellular mycobacteria during 5 d of culture showed that, at
200 mM l-methionine-S-sulfoximine, growth of the bacteria
was strongly inhibited. However, little if any killing of bacteria
occurred. At 2 mM of inhibitor, growth of M. tuberculosis was
slowed, but growth of M. avium was uninhibited. The greater
sensitivity to l-methionine-S-sulfoximine in human mono-
cytes of M. tuberculosis compared with M. avium parallels the
greater sensitivity to this inhibitor under cell-free growth con-
ditions of M. tuberculosis compared with M. avium. This pattern
of sensitivity in turn correlates with the finding that M. tubercu-
losis releases z3–4-fold more glutamine synthetase extracellu-
larly than M. avium.
Figure 4. Effect of l-methionine-S-sulfoximine (MS) on intra- (A) and
extracellular (B) glutamine synthetase activity of cultures of M. tuberculosis
Erdman strain. Standard broth cultures of M. tuberculosis at an initial den-
sity of 105 bacteria/ml supplemented 7H9 medium, in triplicate, were in-
cubated in the presence or absence of the glutamine synthetase inhibitor
l-methionine-S-sulfoximine for 4 wk at 378C in a 5% CO2 atmosphere.
Aliquots of the cultures, containing at least 108 bacteria to allow for reli-
able enzyme activity assays, were removed weekly and separated into a
cell pellet and cell supernatant fraction. Bacterial cell extracts were ob-
tained by treating the pellet with lysozyme/Triton X-100 and crystalline
alumina beads (Fisher Scientific). Glutamine synthetase activity was deter-
mined in both fractions by transfer assay (8) and expressed in mU/108
cells. For each point, the maximum variation was #15%.
Figure 5. Effect of l-methionine-S-sulfoximine (MS) on mycobacterial
growth in human monocytes. THP-1 cells were grown in RPMI 1640 (Ir-
vine Scientific) and differentiated just before the formation of a confluent
monolayer. The monocytes were washed, bovine serum was replaced with
human serum (Irvine Scientific), and the monolayers were infected with M.
tuberculosis Erdman (A) or M. avium 25291 (B) at a multiplicity of infection
of 1. Infection was allowed to proceed for 90 min, after which cells were
washed thoroughly and incubated under standard conditions for the next
3 h. At that time point, one set of replicate cultures was lysed and plated on
agar medium to establish an initial intracellular bacterial count. All other
replicate cultures were incubated further for 2 or 5 d in the presence of 0, 2,
or 200 mM l-methionine-S-sulfoximine before monocytes were lysed and
viable intracellular mycobacteria enumerated. The standard deviation for
triplicate cultures was always #15%.1433 Harth and Horwitz
l-Methionine-S-Sulfoximine Treatment Decreases the Amount
of Poly-l-Glutamate/Glutamine in the M. tuberculosis Cell Wall
but Does Not Affect the Peptidoglycan Chain. Pathogenic, but
not nonpathogenic, mycobacteria release abundant amounts
of glutamine synthetase and contain a large amount of
poly-l-glutamate/glutamine in the bacterial cell wall. The
high correlation between glutamine synthetase export and
the presence of poly-l-glutamate/glutamine in the bacterial
cell wall suggests the possibility that extracellular glutamine
synthetase is involved in construction of the poly-l-gluta-
mate/glutamine cell wall structure. If this is true, then inhi-
bition of extracellular glutamine synthetase might reduce
the amount of this structure. We investigated this hypothe-
sis by assaying the amount of this cell wall structure in M.
tuberculosis organisms grown in the presence of various
amounts of the glutamine synthetase inhibitor l-methio-
nine-S-sulfoximine. The mycobacteria were grown for 2 wk
without inhibitor (to insure a sufficient number of cells for
analysis) and then for 4 wk in the presence of 0, 0.2, 2, 20,
and 200 mM inhibitor, after which the amount of the poly-
l-glutamate/glutamine structure in the cell walls was ana-
lyzed (6). The purity of the isolated polymer ranged from
90 to 95%. The inhibitor caused a marked reduction in the
amount of poly-l-glutamate/glutamine, which decreased
in a dose-dependent fashion from 46 mg/1010 cells in the
absence of inhibitor to 3.2 mg/1010 cells in the presence of
200 mM inhibitor (Table II). Because the isolation proce-
dure results in the hydrolysis of glutamine, we could not
determine the exact ratio of glutamate/glutamine residues.
For comparison, we studied the effect of the inhibitor on
the amount of alanine in the peptidoglycan fraction, which
contains one d- and one l-alanine per peptidoglycan mono-
mer. The purified (.90%) peptidoglycan fraction con-
tained from 21 mg d,l-alanine/1010 cells at 0 mM inhibitor
to 16.6 mg at 200 mM of inhibitor. Thus, in contrast to the
pronounced effect of the inhibitor on the amount of poly-
l-glutamate/glutamine in the cell wall, the inhibitor had only
a minimal effect on the amount of alanine in the cell wall.
To confirm that the effect of l-methionine-S-sulfox-
imine on the poly-l-glutamate/glutamine content of the
mycobacterial cell wall was not a nonspecific consequence of
inhibition of bacterial growth, we studied the effect of two
bactericidal antibiotics, amikacin and rifampin, on the myco-
bacterial cell wall. As shown in Table II, these antibiotics had
little influence on the content of either poly-l-glutamate/
glutamine or d,l-alanine, confirming that their mode of ac-
tion is quite different from that of l-methionine-S-sulfox-
imine and that they do not target, directly or indirectly, these
two structures in the mycobacterial cell wall.
The Glutamine Synthetase Inhibitor l-Methionine-S-Sulfox-
imine Acts Synergistically with Several Conventional Antibiotics Used
in the Treatment of Tuberculosis. The finding that l-methi-
onine-S-sulfoximine markedly reduces the amount of a
cell wall structure that comprises 8–10% of the M. tuberculo-
sis cell wall suggested the possibility that the glutamine syn-
thetase inhibitor affects the integrity of the cell wall. To in-
vestigate this idea, we studied the influence of the inhibitor
on the sensitivity of M. tuberculosis to conventional antibiot-
ics. We cultured M. tuberculosis in the presence of subinhib-
itory concentrations of l-methionine-S-sulfoximine (0.02,
0.2, or 2 mM) and subinhibitory concentrations of each of
four antibiotics: isoniazid, rifampin, pyrazinamide, or etham-
butol. In all cases, bacterial growth in the presence of the
combination of l-methionine-S-sulfoximine and antibiotic
was significantly less than in the presence of either inhibitor
alone. The most pronounced effect on bacterial growth was
observed for isoniazid (Fig. 6 A) and rifampin (Fig. 6 B) at
one-tenth their minimal inhibitory concentrations in combi-
nation with 0.2 mM l-methionine-S-sulfoximine. The anti-
biotics had a negligible effect on intracellular or extracellular
glutamine synthetase activity. This result is consistent with
the hypothesis that the inhibitory effect of l-methionine-
S-sulfoximine on the extracellular glutamine synthetase af-
fects the integrity of the M. tuberculosis cell wall so as to allow
antibiotics greater access to the bacterial cytoplasm.
Discussion
Our study demonstrates that inhibitors of extracellular
glutamine synthetase block the growth of M. tuberculosis
and other pathogenic mycobacteria. Remarkably, the in-
hibitors are selective for pathogenic mycobacteria, which
Table II. Comparison of the Effect of the Glutamine Synthetase Inhibitor L-Methionine-S-Sulfoximine and Two Standard Antibiotics on the 
M. tuberculosis Cell Wall Components Poly-L-Glutamate/Glutamine and Peptidoglycan
l-Methionine-S-Sulfoximine Amikacin Rifampin
mM mg/ml mg/ml
Inhibitor/antibiotic concentration 0 0.2 2 20 200 0.06 0.25 1 0.0125 0.05 0.2
Poly-l-Glutamate/glutamine
(mg/1010 Cells) 46 18.2 9.8 6.1 3.2 49.9 43.2 26.0a 54.2 41.6 40.0a
d,l-Alanine (mg/1010 Cells) 21 21.2 17.7 17.8 16.6 29.1 26.3 12.0a 23.6 25.1 20.0a
aAt high concentrations, amikacin (1 mg/ml) and rifampin (0.2 mg/ml) were lytic for M. tuberculosis. Consequently, the values shown for poly-
l-glutamate/glutamine and d,l-alanine at these concentrations of antibiotic are calculated on the basis of ,1–5 3 107 cells for 1 mg/ml amikacin and
107 cells for 0.2 mg/ml rifampin.
The SD for all presented values was #15%.1434 Novel Drug Targets of M. tuberculosis
export glutamine synthetase and contain the poly-l-gluta-
mate/glutamine cell wall structure. The correlation be-
tween export of glutamine synthetase and the presence of
this cell wall structure revealed in our previous study led us
to hypothesize that exported glutamine synthetase is involved
in the synthesis of this major cell wall component, the
function of which remains elusive. The study here, demon-
strating that inhibition of extracellular glutamine synthetase
is associated with a marked diminution in the cell wall
structure, lends further support to this hypothesis. That this
in turn is correlated with bacteriostasis suggests that the
poly-l-glutamate/glutamine structure plays an important
role in the homeostasis of pathogenic mycobacteria.
Extracellular glutamine synthetase is clearly a prime tar-
get of the irreversible glutamine synthetase inhibitor l-methi-
onine-S-sulfoximine. The inhibitor reduced glutamine
synthetase activity in the extracellular milieu of M. tubercu-
losis cultures by 80% but had little effect on cell-associated
glutamine synthetase. Indeed, given the formidable barrier
presented by the lipid-rich cell wall of M. tuberculosis, the
small amount of cell-associated enzyme that is affected by
l-methionine-S-sulfoximine may be an enzyme that has in
fact cleared the bacterial cell membrane but not yet been
released by the bacterium.
That the glutamine synthetase inhibitor l-methionine-
S-sulfoximine selectively blocks the growth of mycobacteria
that export a large proportion of their glutamine synthetase
suggests that inhibition of glutamine synthetase may be di-
rectly responsible for the bacteriostatic effect of the inhibi-
tor. However, inactivation of additional extracellular targets
by l-methionine-S-sulfoximine, such as enzymes involved
in the synthesis and cell wall anchoring of the heteropoly-
mer poly-l-glutamate/glutamine, may contribute to the ob-
served bacteriostatic effect of this inhibitor.
In addition to inhibiting glutamine synthetase, l-methi-
onine-S-sulfoximine inhibits g-glutamylcysteine synthetase,
which catalyzes a chemical reaction very similar to the one
catalyzed by glutamine synthetase. However, the inhibitor’s
effect on this enzyme is reversible, in contrast to the case
with glutamine synthetase (19). Whether this typically in-
tracellular enzyme is exported by M. tuberculosis is not known.
However, if it is, the amount exported must be very small
compared with glutamine synthetase as, unlike glutamine
synthetase, g-glutamylcysteine synthetase is not one of the
12 most abundant proteins exported by M. tuberculosis.
New antibiotics are desperately needed to combat the
rapidly emerging strains of M. tuberculosis that are resistant
to conventional antibiotics. However, M. tuberculosis pre-
sents a formidable challenge to the design of antibiotics.
First, the antibiotic must penetrate the host cell and reach
the organism within its unique intracellular compartment, a
specialized, membrane-bound phagosome (3). Second, the
antibiotic must reach its molecular target, generally within
the organism, in which case the thick waxy coat of the my-
cobacterium presents an additional major obstacle. Our study
provides an approach to circumventing the second major
obstacle, targeting an extracellular enzyme crucial to bacte-
rial cell growth. Specifically, our study demonstrates that
treatment of M. tuberculosis with a drug that inactivates
extracellular glutamine synthetase inhibits mycobacterial
growth. Hence, drugs functionally analogous to l-methi-
onine-S-sulfoximine, but perhaps with even greater speci-
ficity for the M. tuberculosis enzyme relative to the mamma-
lian enzyme, have great potential as antibiotics against this
pathogen. Our demonstration that l-methionine-S-sulfoxi-
mine inhibits M. tuberculosis growing within its host cell,
the human mononuclear phagocyte, underscores the feasi-
bility of this approach.
More generally, our study suggests that other extracellu-
lar enzymes of M. tuberculosis and other pathogenic myco-
bacteria, and even nonmycobacterial pathogens, may serve
Figure 6. Influence of l-methionine-S-sulfoximine (MS) on the growth
of M. tuberculosis in the presence of subinhibitory concentrations of the anti-
biotics (A) isoniazid (INH) and (B) rifampin (RIF). M. tuberculosis Erdman
cultures at an initial density of 105 cells/ml medium were incubated at 378C
in a 5% CO2 atmosphere for 6 wk in the presence or absence of either iso-
niazid or rifampin and/or the glutamine synthetase inhibitor l-methionine-
S-sulfoximine. The chosen concentrations of the antibiotics and the en-
zyme inhibitor corresponded to approximately one-tenth of their minimal
inhibitory concentrations. For the enumeration of viable bacteria in each
culture, aliquots were removed weekly, diluted, plated on solid medium,
and incubated for 2 wk at 378C in a 5% CO2 atmosphere in the absence of
any inhibitor. The SD for triplicate cultures was always #15%.1435 Harth and Horwitz
as readily accessible targets of antibiotics. In this regard, an
obvious mycobacterial target is the 30/32-kD protein com-
plex, the most abundant proteins released by M. tuberculosis
(2, 20). These unique extracellular enzymes of pathogenic
mycobacteria, which have been reported to have mycolyl
transferase activity (21), presumably serve an essential role
in microbial physiology and pathogenicity and represent
highly specific targets for antibiotics.
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